Aura Biosciences, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Aura Biosciences, Inc. (AURA) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$22.28 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-30
- Aura Biosciences, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$22.28M.
- Aura Biosciences, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$18.23M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$22.28M 10-K · filed 2026-03-30 |
| 2024-12-31 | -$18.23M 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |